Sacituzumab Govitecan-hiy
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Metastatic Solid Tumors
Conditions
Metastatic Solid Tumors
Trial Timeline
Aug 4, 2020 → Oct 18, 2024
NCT ID
NCT04319198About Sacituzumab Govitecan-hiy
Sacituzumab Govitecan-hiy is a approved stage product being developed by Gilead Sciences for Metastatic Solid Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT04319198. Target conditions include Metastatic Solid Tumors.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Solid Tumors were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04319198 | Approved | Completed |
Competing Products
20 competing products in Metastatic Solid Tumors